• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: NiVB G protein
• G glycoprotein gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Foster et al., 2022)
  • Detailed Gene Information: Click Here.
• Vector: recombinant vesicular stomatitis virus (Foster et al., 2022)
• Immunization Route: Intramuscular injection (i.m.)
• Description: A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease. (Foster et al., 2022)

Monkey Response

• Vaccination Protocol: For both studies, nine healthy, adult AGMs (African green monkey) were randomized into a group of six experimental animals and a group of three control animals. The six experimental animals were specifically vaccinated by intramuscular injection of 1 × 10^7 PFU of rVSV-ΔG-NiVBG, and control animals were vaccinated by intramuscular injection of 1 × 10^7 PFU of a nonspecific rVSVΔG-EBOV-GP vaccine. (Foster et al., 2022)
• Immune Response: All survivors in study 1 and study 2 developed neutralizing antibodies beginning at 7 DPI. Interestingly, animals in study 2 exhibited higher neutralizing antibody titers than subjects in study 1, suggesting a stronger humoral response may be needed to control infection whenever the vaccine is administered at a shorter interval. None of the vector control nor specifically vaccinated animals that succumbed to NiV disease developed neutralizing antibodies. (Foster et al., 2022)
• Challenge Protocol: For the first study, all nine AGMs were exposed 7 d after vaccination to 5 × 105 PFU of NiVB, with the dose being equally divided between intratracheal and the intranasal routes. For the second study, all AGMs were exposed 3 d after vaccination to 5 × 10^5 PFU of NiVB with the dose being equally divided between the intratracheal and the intranasal routes. (Foster et al., 2022)
• Efficacy: All monkeys vaccinated with rVSV-ΔG-NiVBG 7 d prior to NiVB exposure were protected from lethal disease, while 67% of animals vaccinated 3 d before NiVB challenge survived. (Foster et al., 2022)